person · Reporting owner

Dugel Pravin

Disclosed activity across 3 companies

Tapewire entity: 19410
SEC CIK: 0001700917

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
OCULAR THERAPEUTIX, INCOCUL · Entity 273	Director · See Remarks	August 24, 2026	August 26, 2026
Whitehawk Therapeutics, Inc.ARPO · Entity 6074	Director	June 30, 2021	July 02, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

OCULAR THERAPEUTIX, INC

Report date August 24, 2026 · Filed August 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,525,429	Reported balance After 2026-08-24 transaction · row 1 1 source row Row 1 · 2026-08-24 · Sale · Disposed 21,649 · Balance 2,525,429 F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6400 to $10.9000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Common StockSEC Table I · non-derivative	IndirectBy spouse	0	Reported balance After 2026-08-25 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-08-25 · Gift · Disposed 50,092 · Balance 0 F3: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.
Common StockSEC Table I · non-derivative	IndirectBy Pravin Dugel 2024 Irrevocable Trust	744,903	Reported balance After 2026-08-25 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-25 · Gift · Acquired 50,092 · Balance 744,903 F3: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6400 to $10.9000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.

Whitehawk Therapeutics, Inc.

Report date June 30, 2021 · Filed July 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,568	Reported balance After 2021-06-30 transaction · row 1 1 source row Row 1 · 2021-06-30 · Grant · Acquired 6,331 · Balance 12,568 F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

IVERIC bio, Inc.

Report date July 11, 2023 · Filed July 13, 2023

Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-07-11 transaction · row 1 1 source row Row 1 · 2023-07-11 · Disposition to issuer · Disposed 203,035 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-07-11 · Disposition to issuer · Disposed 8,625 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-07-11 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-07-11 · Disposition to issuer · Disposed 37,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-07-11 · Disposition to issuer · Disposed 70,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-07-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-07-11 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2030-03-31	Direct	Reported balance After 2023-07-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-07-11 · Disposition to issuer · Disposed 300,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2030-12-17	Direct	Reported balance After 2023-07-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-07-11 · Disposition to issuer · Disposed 110,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.17 · Expires 2031-05-02	Direct	Reported balance After 2023-07-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-07-11 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.83 · Expires 2031-12-16	Direct	Reported balance After 2023-07-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-07-11 · Disposition to issuer · Disposed 100,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2032-12-19	Direct	Reported balance After 2023-07-11 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-07-11 · Disposition to issuer · Disposed 140,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.

F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 25, 2026 Filed Aug 26, 2026 21:56 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	50,092	$0.00	$0.00	Disclosure SEC source: 0001104659-26-101667 · tm2624096-1_4seq1.xml · nonDerivative · entry 3 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · By Pravin Dugel 2024 Irrevocable Trust Disclosed balance after: 744,903 F3 · kind: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. Read SEC document
August 25, 2026 Filed Aug 26, 2026 21:56 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	50,092	$0.00	$0.00	Disclosure SEC source: 0001104659-26-101667 · tm2624096-1_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · By spouse Disclosed balance after: 0 F3 · kind: On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. Read SEC document
August 24, 2026 Filed Aug 26, 2026 21:56 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	21,649	$10.77	$233,159.73	Disclosure SEC source: 0001104659-26-101667 · tm2624096-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,525,429 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6400 to $10.9000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
June 16, 2026 Filed Jun 18, 2026 20:01 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	50,092	$0.00	$0.00	Disclosure SEC source: 0001104659-26-075709 · tm2618141-1_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 50,092 F1 · kind: On June 16, 2026, the reporting person transferred 50,092 shares to his spouse for no consideration. Read SEC document
June 16, 2026 Filed Jun 18, 2026 20:01 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	50,092	$0.00	$0.00	Disclosure SEC source: 0001104659-26-075709 · tm2618141-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,547,078 F1 · kind: On June 16, 2026, the reporting person transferred 50,092 shares to his spouse for no consideration. Read SEC document
May 28, 2026 Filed May 28, 2026 20:08 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	394,696	$0.00	$0.00	Disclosure SEC source: 0001104659-26-067485 · tm2615856-4_4seq1.xml · nonDerivative · entry 3 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · By Pravin Dugel 2024 Irrevocable Trust Disclosed balance after: 694,811 F3 · kind: On May 28, 2026, the reporting person's spouse transferred 394,696 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. Read SEC document
May 28, 2026 Filed May 28, 2026 20:08 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	394,696	$0.00	$0.00	Disclosure SEC source: 0001104659-26-067485 · tm2615856-4_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · By spouse Disclosed balance after: 0 F3 · kind: On May 28, 2026, the reporting person's spouse transferred 394,696 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. Read SEC document
May 26, 2026 Filed May 28, 2026 20:08 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	21,156	$8.20	$173,479.20	Disclosure SEC source: 0001104659-26-067485 · tm2615856-4_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,597,170 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1450 to $8.2521, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
April 09, 2026 Filed Apr 13, 2026 21:15 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	394,696	$0.00	$0.00	Disclosure SEC source: 0001104659-26-042694 · tm2611637-1_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 394,696 F1 · kind: On April 9, 2026, the reporting person transferred 394,696 shares to his spouse for no consideration. Read SEC document
April 09, 2026 Filed Apr 13, 2026 21:15 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	394,696	$0.00	$0.00	Disclosure SEC source: 0001104659-26-042694 · tm2611637-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,618,326 F1 · kind: On April 9, 2026, the reporting person transferred 394,696 shares to his spouse for no consideration. Read SEC document
February 23, 2026 Filed Feb 25, 2026 23:20 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	20,056	$8.28	$166,063.68	Disclosure SEC source: 0001104659-26-019805 · tm267255-4_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,013,022 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2100 to $8.3700, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
February 12, 2026 Filed Feb 18, 2026 01:29 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	124,882	$9.04	$1,128,933.28	Disclosure SEC source: 0001104659-26-016666 · tm266494-2_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,033,078 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.9900 to $9.0850, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
November 26, 2025 Filed Nov 26, 2025 21:02 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	49,754	$0.00	$0.00	Disclosure SEC source: 0001104659-25-116424 · tm2532258-3_4seq1.xml · nonDerivative · entry 3 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · By Pravin Dugel 2024 Irrevocable Trust Disclosed balance after: 300,115 F3 · kind: On November 26, 2025, the reporting person's spouse transferred 49,754 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. Read SEC document
November 26, 2025 Filed Nov 26, 2025 21:02 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	49,754	$0.00	$0.00	Disclosure SEC source: 0001104659-25-116424 · tm2532258-3_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · By spouse Disclosed balance after: 0 F3 · kind: On November 26, 2025, the reporting person's spouse transferred 49,754 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. Read SEC document
November 24, 2025 Filed Nov 26, 2025 21:02 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	19,530	$12.04	$235,141.20	Disclosure SEC source: 0001104659-25-116424 · tm2532258-3_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,157,960 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.74 to $12.34, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
September 09, 2025 Filed Sep 11, 2025 20:06 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	49,754	$0.00	$0.00	Disclosure SEC source: 0001410578-25-002028 · tm2525848-1_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 49,754 F1 · kind: On September 9, 2025, the reporting person transferred 49,754 shares to his spouse for no consideration. Read SEC document
September 09, 2025 Filed Sep 11, 2025 20:06 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	49,754	$0.00	$0.00	Disclosure SEC source: 0001410578-25-002028 · tm2525848-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,177,490 F1 · kind: On September 9, 2025, the reporting person transferred 49,754 shares to his spouse for no consideration. Read SEC document
August 25, 2025 Filed Aug 27, 2025 22:41 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	21,494	$12.04	$258,787.76	Disclosure SEC source: 0001104659-25-084113 · tm2524438-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,227,244 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.89 to $12.18, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
August 11, 2025 Filed Aug 13, 2025 23:02 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	250,361	$0.00	$0.00	Disclosure SEC source: 0001104659-25-077724 · tm2523457-1_4seq1.xml · nonDerivative · entry 3 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Pravin Dugel 2024 Irrevocable Trust Disclosed balance after: 250,361 F3 · kind: On August 11, 2025, the reporting person's spouse transferred 250,361 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust. Read SEC document
June 12, 2025 Filed Aug 13, 2025 23:02 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	50,029	$0.00	$0.00	Disclosure SEC source: 0001104659-25-077724 · tm2523457-1_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,248,738 F2 · kind: On June 12, 2025, the reporting person transferred 50,029 shares to his spouse for no consideration. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:26 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GrantPerformance Stock Option (Right to Buy) · Derivative	2,750,000	$0.00 Strike: $7.44	$0.00	Disclosure SEC source: 0001104659-25-059393 · tm2517945-7_4seq1.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750,000 Underlying: Common Stock · 2,750,000 shares Expires 2035-02-11 F1 · date: The performance stock option grant was approved by the Board of Directors of Ocular Therapeutix, Inc. (the "Corporation") on February 11, 2025 (the "Grant Date"), the commencement of vesting of which was contingent upon shareholder approval of an amendment to the Corporation's 2021 Stock Incentive Plan, as amended. Shareholder approval of such amendment was received on June 11, 2025. F2 · derivative.exercise_date: Pursuant to a performance stock option agreement (the "Option Agreement"), the shares underlying the performance stock option can be earned during the five-year period beginning on the Grant Date in four equal tranches based on the achievement of share price hurdles if the Corporation's consecutive 60-day closing share price average meets or exceeds $15.00, $20.00, $25.00, and $30.00 per share (each, a "Share Price Hurdle"). Shares underlying the performance stock option that are earned shall vest on the later of (i) the achievement of the applicable Share Price Hurdle or (ii) the three-year anniversary of the Grant Date, in each case subject to the reporting person's continued service to the Corporation. The performance stock option is subject to earlier vesting upon certain qualifying termination events pursuant to the Option Agreement. Read SEC document
May 23, 2025 Filed May 27, 2025 21:37 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	21,219	$7.18	$152,352.42	Disclosure SEC source: 0001104659-25-053087 · tm2516174-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,499,099 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.02 to $7.29, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
April 28, 2025 Filed Aug 13, 2025 23:02 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GiftCommon Stock	200,332	$0.00	$0.00	Disclosure SEC source: 0001104659-25-077724 · tm2523457-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,298,767 F1 · kind: On April 28, 2025, the reporting person transferred 200,332 shares to his spouse for no consideration. Read SEC document
February 24, 2025 Filed Feb 26, 2025 23:27 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	21,475	$6.87	$147,533.25	Disclosure SEC source: 0001104659-25-017568 · tm257640-4_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,520,318 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.79 to $6.97, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
February 11, 2025 Filed Feb 14, 2025 01:38 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GrantCommon Stock	1,500,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-013156 · tm256513-4_4seq1.xml · nonDerivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,541,793 F2 · shares: On the Grant Date, the reporting person was granted performance stock units ("PSUs") under the 2021 Plan and in accordance with a PSU award agreement (the "PSU Award Agreement"). F3 · shares: Each PSU represents a right to receive one share of the Corporation's common stock. Pursuant to the PSU Award Agreement, the shares underlying the PSUs can be earned during the five-year period beginning on the Grant Date in four equal tranches based on the achievement of share price hurdles if the Company's consecutive 60-day closing share price average meets or exceeds $15.00, $20.00, $25.00, and $30.00 per share (each, a "Share Price Hurdle"). Shares underlying the PSUs that are earned shall vest on the later of (i) the achievement of the applicable Share Price Hurdle or (ii) the three-year anniversary of the Grant Date, in each case subject to the reporting person's continued service to the Corporation. The PSUs are subject to earlier vesting upon certain qualifying termination events pursuant to the PSU Award Agreement. Read SEC document
February 11, 2025 Filed Feb 14, 2025 01:38 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GrantCommon Stock	1,250,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-013156 · tm256513-4_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,041,793 F1 · shares: On February 11, 2025 (the "Grant Date"), the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended (the "2021 Plan"), of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the Grant Date and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. Read SEC document
November 25, 2024 Filed Nov 27, 2024 12:47 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	20,680	$9.01	$186,326.80	Disclosure SEC source: 0001104659-24-123407 · tm2429613-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 791,793 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2024. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2024. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.88 to $9.11, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
August 23, 2024 Filed Aug 27, 2024 21:17 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	20,880	$9.02	$188,337.60	Disclosure SEC source: 0001104659-24-093500 · tm2422748-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 812,473 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2024. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2024. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.88 to $9.14, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
May 23, 2024 Filed May 28, 2024 21:00 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	SaleCommon Stock	21,626	$5.79	$125,214.54	Disclosure SEC source: 0001104659-24-065644 · tm2415610-1_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 833,353 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2024. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2024. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.74 to $5.81, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
February 22, 2024 Filed Feb 27, 2024 01:07 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GrantStock Option (Right to Buy) · Derivative	1,282,469	$0.00 Strike: $9.70	$0.00	Disclosure SEC source: 0001104659-24-027726 · tm247229-4_4seq1.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,282,469 Underlying: Common Stock · 1,282,469 shares Expires 2024-02-21 F2 · derivative.exercise_date: Vests over four years, vesting in equal monthly installments beginning on the date the reporting person commenced employment with the Corporation. Read SEC document
February 22, 2024 Filed Feb 27, 2024 01:07 UTC	OCULAR THERAPEUTIX, INC OCUL · Entity 273	GrantCommon Stock	854,979	$0.00	$0.00	Disclosure SEC source: 0001104659-24-027726 · tm247229-4_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 854,979 F1 · shares: On February 22, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal quarterly installments, beginning on the date of grant. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerStock Option (Right to Buy) · Derivative	140,000	Not disclosed Strike: $22.57	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 11 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2032-12-19 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerStock Option (Right to Buy) · Derivative	100,000	Not disclosed Strike: $14.83	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 10 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-12-16 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerStock Option (Right to Buy) · Derivative	35,000	Not disclosed Strike: $7.17	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 9 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2031-05-02 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerStock Option (Right to Buy) · Derivative	110,000	Not disclosed Strike: $7.50	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 8 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2030-12-17 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerStock Option (Right to Buy) · Derivative	300,000	Not disclosed Strike: $3.16	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 7 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2030-03-31 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	27,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 6 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,500 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	70,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 5 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	37,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 4 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	50,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 3 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerRestricted Stock Units · Derivative	8,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,625 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document
July 11, 2023 Filed Jul 13, 2023 13:57 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Disposition to issuerCommon Stock	203,035	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-080684 · tm2321002-5_4seq1.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. Read SEC document
May 03, 2023 Filed May 11, 2023 17:15 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	4,312	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000066 · wk-form4_1683839712.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,625 Underlying: Common Stock · 4,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F2 · derivative.exercise_date: On May 3, 2021, the Reporting Person was granted 17,250 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. F2 · derivative.expiration_date: On May 3, 2021, the Reporting Person was granted 17,250 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. Read SEC document
May 03, 2023 Filed May 11, 2023 17:15 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	4,312	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000066 · wk-form4_1683839712.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. Read SEC document
April 01, 2023 Filed Apr 4, 2023 16:27 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	50,000	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000036 · wf-form4_168064001228012.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F2 · derivative.exercise_date: On April 1, 2020, the Reporting Person was granted 200,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. F2 · derivative.expiration_date: On April 1, 2020, the Reporting Person was granted 200,000 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan. Read SEC document
April 01, 2023 Filed Apr 4, 2023 16:27 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	50,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001410939-23-000036 · wf-form4_168064001228012.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. Read SEC document
January 02, 2023 Filed Jan 4, 2023 18:35 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionRestricted Stock Units · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000010 · wf-form4_167287529901645.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. F2 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 50,000 restricted stock units, which vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. F2 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 50,000 restricted stock units, which vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan. Read SEC document
January 02, 2023 Filed Jan 4, 2023 18:35 UTC	IVERIC bio, Inc. ISEE · Entity 111416	Exercise / conversionCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0001410939-23-000010 · wf-form4_167287529901645.xml · nonDerivative · entry 1 Dugel Pravin · CIK 0001700917 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. Read SEC document
December 20, 2022 Filed Dec 22, 2022 18:55 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantRestricted Stock Units · Derivative	70,000	$0.00	$0.00	Disclosure SEC source: 0001410939-22-000148 · wf-form4_167175331286363.xml · derivative · entry 2 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). Read SEC document
December 20, 2022 Filed Dec 22, 2022 18:55 UTC	IVERIC bio, Inc. ISEE · Entity 111416	GrantStock Option (right to buy) · Derivative	140,000	$0.00 Strike: $22.57	$0.00	Disclosure SEC source: 0001410939-22-000148 · wf-form4_167175331286363.xml · derivative · entry 1 Dugel Pravin · CIK 0001700917 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.